Pykus Therapeutics, Inc. ("Pykus" or the "Company"), a clinical-stage medical technology company, announced today that it will present an overview of its investigational retinal sealant, PYK-2101, at ...
The FDA granted fast track designation to ATSN-201 for the treatment of X-linked retinoschisis, according to a press release ...
High levels of exposure to air pollution can increase the incidence of diabetic retinopathy and glaucoma, a recent study ...
Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that the U.S. Food and Drug ...
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced their abstract of a preclinical study of KIO ...
Age-related macular degeneration (AMD) AMD is a common eye condition that happens as you get older. It affects the macula, ...
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of ...
NY Retina, a newly launched ophthalmology practice, is set to open March 20 in a newly purchased medical office building in ...
Usha (name changed), 62, was experiencing sudden and painless loss of vision in the right eye for one day when she turned up ...
In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...
BCVA 1 week after macula-off rhegmatogenous retinal detachment surgery most effectively predicts patients’ long-term visual outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback